Tu Dan

Dr. Tu Dan

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CSCharles Simone
Charles Simone
DLDavid Ly
David Ly
TDTu Dan
Tu Dan
JOJohn Ondos
John Ondos
HNHolly Ning
Holly Ning
NSNicole L. Simone
Nicole L. Simone

15 June 2013 in Cell Cycle
Verified
Journal Article
Open access
ASAnthony Saleh
Anthony Saleh
BSBrittany Simone
Brittany Simone
JPJuan Palazzo
Juan Palazzo
JSJason E. Savage
Jason E. Savage
YSYuri Sano
Yuri Sano
NSNicole L. Simone
Nicole L. Simone
Dietary modification such as caloric restriction (CR) has been shown to decrease tumor initiation and progression. We sought to determine if nutrient restriction could be used as a novel therapeuti...

24 November 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
NSNicole L. Simone
Nicole L. Simone
TDTu Dan
Tu Dan
JSJoanna Shih
Joanna Shih
SSSharon L. Smith
Sharon L. Smith
LSLinda Sciuto
Linda Sciuto
KCKevin Camphausen
Kevin Camphausen

1 February 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EZElizabeth Ren Zhang-Velten
Elizabeth Ren Zhang-Velten
DPDavid Donald Mortimer Parsons
David Donald Mortimer Parsons
PLPam Lee
Pam Lee
ECEric Chambers
Eric Chambers
RARamzi Abdulrahman
Ramzi Abdulrahman
XGXuejun Gu
Xuejun Gu
Total body irradiation is an important part of the conditioning regimens frequently used to prepare patients for allogeneic hematopoietic stem cell transplantation (SCT). Volumetric-modulated arc therapy enabled total body irradiation (VMAT-TBI), an alternative to conventional TBI (cTBI), is a novel radiotherapy treatment technique that has been implemented and investigated in our institution. The purpose of this study is to (1) report our six-year clinical experience in terms of treatment planning strategy and delivery time and (2) evaluate the clinical outcomes and toxicities in our cohort of patients treated with VMAT-TBI. This is a retrospective single center study. Forty-four patients at our institution received VMAT-TBI and chemotherapy conditioning followed by allogeneic SCT between 2014 and 2020. Thirty-two patients (73%) received standard-dose TBI (12-13.2 Gy in 6-8 fractions twice daily), whereas 12 (27%) received low-dose TBI (2-4 Gy in one fraction). Treatment planning, delivery, and treatment outcome data including overall survival (OS), relapse-free survival (RFS), and toxicities were analyzed. The developed VMAT-TBI planning strategy consistently generated plans satisfying our dose constraints, with planning target volume coverage >90%, mean lung dose ∼50% to 75% of prescription dose, and minimal hotspots in critical organs. Most of the treatment deliveries were <100 minutes (range 33-147, mean 72). The median follow-up was 26 months. At the last follow-up, 34 of 44 (77%) of patients were alive, with 1- and 2-year OS of 90% and 79% and RFS of 88% and 71%, respectively. The most common grade 3+ toxicities observed were mucositis (31 patients [71%]) and nephrotoxicity (6 patients [13%]), both of which were deemed multifactorial in cause. Four patients (9%) in standard-dose cohort developed grade 3+ pneumonitis, with 3 cases in the setting of documented respiratory infection and only 1 (2%) deemed likely related to radiation alone. VMAT-TBI provides a safe alternative to cTBI. The dose modulation capability of VMAT-TBI may lead to new treatment strategies, such as simultaneous boost and further critical organ sparing, for better malignant cell eradication, immune suppression, and lower toxicities.

20 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TDTu Dan
Tu Dan
ASAnuradha Shastri
Anuradha Shastri
APAjay Palagani
Ajay Palagani
SBSimone Buraschi
Simone Buraschi
TNThomas Neill
Thomas Neill
NSNicole L. Simone
Nicole L. Simone
Breast cancer (BrCa) relies on specific microRNAs to drive disease progression. Oncogenic miR-21 is upregulated in many cancers, including BrCa, and is associated with poor survival and treatment resistance. We sought to determine the role of miR-21 in BrCa tumor initiation, progression and treatment response. In a triple-negative BrCa model, radiation exposure increased miR-21 in both primary tumor and metastases. In vitro, miR-21 knockdown decreased survival in all BrCa subtypes in the presence of radiation. The role of miR-21 in BrCa initiation was evaluated by implanting wild-type miR-21 BrCa cells into genetically engineered mouse models where miR-21 was intact, heterozygous or globally ablated. Tumors were unable to grow in the mammary fat pads of miR-21−/− mice, and grew in ~50% of miR-21+/− and 100% in miR-21+/+ mice. The contribution of miR-21 to progression and metastases was tested by crossing miR-21−/− mice with mice that spontaneously develop BrCa. The global ablation of miR-21 significantly decreased the tumorigenesis and metastases of BrCa, while sensitizing tumors to radio- and chemotherapeutic agents via Fas/FasL-dependent apoptosis. Therefore, targeting miR-21 alone or in combination with various radio or cytotoxic therapies may represent novel and efficacious therapeutic modalities for the future treatment of BrCa patients.

26 November 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TDTu Dan
Tu Dan
SHStephen M Hewitt
Stephen M Hewitt
NON. Ohri
N. Ohri
DLD. Ly
D. Ly
BSB. P. Soule
B. P. Soule
NSNicole L. Simone
Nicole L. Simone